Utilizing gene-editing technologies such as CRISPR/Cas9 to selectively knock out components of the PI3K-AKT pathway in tumor cells while sparing normal cells offers high specificity for precise targeting of cancer cells without affecting healthy tissue (Matano et al., 2015; Faulkner et al., 2020; Bao et al., 2022; Singh et al., 2023). This evidence concerns the gene AKT1 and cancer.